BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $373,000 | +62.2% | 1,890 | +67.6% | 0.01% | +50.0% |
| Q3 2018 | $230,000 | -26.5% | 1,128 | -57.8% | 0.00% | -42.9% |
| Q2 2017 | $313,000 | +12.6% | 2,671 | -2.4% | 0.01% | 0.0% |
| Q1 2017 | $278,000 | -53.0% | 2,737 | -52.7% | 0.01% | -46.2% |
| Q4 2016 | $591,000 | -5.9% | 5,788 | +0.3% | 0.01% | -18.8% |
| Q3 2016 | $628,000 | -5.4% | 5,772 | -2.2% | 0.02% | -20.0% |
| Q2 2016 | $664,000 | +17.3% | 5,903 | -1.8% | 0.02% | +11.1% |
| Q1 2016 | $566,000 | +8.6% | 6,010 | +3.2% | 0.02% | +5.9% |
| Q4 2015 | $521,000 | -3.2% | 5,825 | -0.4% | 0.02% | -10.5% |
| Q3 2015 | $538,000 | -13.1% | 5,850 | -7.4% | 0.02% | -5.0% |
| Q2 2015 | $619,000 | -7.5% | 6,318 | -5.6% | 0.02% | -9.1% |
| Q1 2015 | $669,000 | +9.5% | 6,696 | +1.0% | 0.02% | +10.0% |
| Q4 2014 | $611,000 | – | 6,632 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
| Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
| Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
| Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
| Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
| STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
| DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
| MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
| Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
| Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |